Use: Labeled indications
- INDICATIONS AND USAGE Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma.
Full indications and usage US FDA label
INDICATIONS AND USAGE Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months.
However, caution should be used in treating patients with severe reactive airway disease or a history of asthma.
Contraindications
CONTRAINDICATIONS Hypersensitivity to any component of this product. Betaxolol Hydrochloride Ophthalmic Solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION The recommended dose is one to two drops of Betaxolol Hydrochloride Ophthalmic Solution in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to Betaxolol Hydrochloride Ophthalmic Solution may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised. If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors can be instituted.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 5 mg/mL
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Betaxolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BertocilBetaxolol (as hydrochloride) | 5 mg/mL (0.5% w/v) Ophthalmic Solution (Drops)10 mL Opaque White LDPE Dropper Tip Bottle (Box of 1's) | RxVAT-exempt | Laboratorio Edol - Produtos Farmaceuticos, S.A.Portugal | Ambicare Pharmaceuticals Inc. | DRP-10833 | Dec 6, 2031 | |
IobetBetaxolol (as Hydrochloride) | 5 mg / mL (0.5% w/v) Ophthalmic Solution (Eye Drops)5 mL LDPE vial (Box of 1's) | RxVAT-exempt | FDC LimitedIndia | Penta Labs Australia (Philippines) | DRP-5295 | May 15, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNING Topically applied beta-adrenergic blocking agents may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents.
Betaxolol Hydrochloride Ophthalmic Solution has been shown to have a minor effect on heart rate and blood pressure in clinical studies. Caution should be used in treating patients with a history of cardiac failure or heart block. Treatment with Betaxolol Hydrochloride Ophthalmic Solution should be discontinued at the first signs of cardiac failure.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Patients who are receiving a beta-adrenergic blocking agent orally and Betaxolol Hydrochloride Ophthalmic Solution should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade. Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia.
Betaxolol is an adrenergic blocking agent; therefore, caution should be exercised in patients using concomitant adrenergic psychotropic drugs.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The following adverse reactions have been reported in clinical trials with Betaxolol Hydrochloride Ophthalmic Solution. Ocular Discomfort of short duration was experienced by one in four patients, but none discontinued therapy; occasional tearing has been reported. Rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctate staining, keratitis, anisocoria, edema, and photophobia have been reported.
Additional medical events reported with other formulations of betaxolol include blurred vision, foreign body sensation, dryness of the eyes, inflammation, discharge, ocular pain, decreased visual acuity, and crusty lashes. Systemic Systemic reactions following administration of Betaxolol Hydrochloride Ophthalmic Solution 0.5% or Betaxolol Hydrochloride Ophthalmic Suspension 0.25% have been rarely reported.
These include: Cardiovascular Bradycardia, heart block and congestive failure. Pulmonary Pulmonary distress characterized by dyspnea, bronchospasm, thickened bronchial secretions, asthma and respiratory failure. Central Nervous System Insomnia, dizziness, vertigo, headaches, depression, lethargy, and increase in signs and symptoms of myasthenia gravis.
Other Hives, toxic epidermal necrolysis, hair loss and glossitis. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Reproduction, teratology, and peri- and postnatal studies have been conducted with orally administered betaxolol HCl in rats and rabbits. There was evidence of drug related postimplantation loss in rabbits and rats at dose levels above 12 mg/kg and 128 mg/kg, respectively. Betaxolol HCl was not shown to be teratogenic, however, and there were no other adverse effects on reproduction at subtoxic dose levels.
There are no adequate and well-controlled studies in pregnant women. Betaxolol Hydrochloride Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether betaxolol HCl is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Betaxolol Hydrochloride Ophthalmic Solution is administered to nursing women.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Betaxolol Hydrochloride, a cardioselective (beta-1-adrenergic) receptor blocking agent, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic blocking agents reduce cardiac output in healthy subjects and patients with heart disease.
In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function. When instilled in the eye, Betaxolol Hydrochloride Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma.
Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters. Ophthalmic betaxolol (one drop in each eye) was compared to timolol and placebo in a three-way crossover study challenging nine patients with reactive airway disease who were selected on the basis of having at least a 15% reduction in the forced expiratory volume in one second (FEV 1) after administration of ophthalmic timolol.
Betaxolol HCl had no significant effect on pulmonary function as measured by FEV 1, Forced Vital Capacity (FVC) and FEV 1 /VC. Additionally, the action of isoproterenol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol. In contrast, ophthalmic timolol significantly decreased these pulmonary functions.
FEV 1 - Percent Change from Baseline 1 Means Betaxolol 1.0% a Timolol 0.5% Placebo Baseline 1.6 1.4 1.4 60 Minutes 2.3 -25.7* 5.8 120 Minutes 1.6 -27.4* 7.5 240 Minutes -6.4 -26.9* 6.9 Isoproterenol b 36.1 -12.4* 42.8 1 Schoene, R. B. et al., Am. J. Ophthal. 97:86, 1984. a Twice the clinical concentration. b Inhaled at 240 minutes; measurement at 270 minutes. *Timolol statistically different from betaxolol and placebo (p < 0.05).
No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, three-way crossover study in 24 normal subjects comparing ophthalmic betaxolol, timolol and placebo for effect on blood pressure and heart rate. Mean arterial blood pressure was not affected by any treatment; however, ophthalmic timolol produced a significant decrease in the mean heart rate.
Mean Heart Rates 1 TREATMENT Bruce Stress Exercise Test Minutes Betaxolol 1% a Timolol 0.5% Placebo 0 79.2 79.3 81.2 2 130.2 126.0 130.4 4 133.4 128.0* 134.3 6 136.4 129.2* 137.9 8 139.8 131.8* 139.4 10 140.8 131.8* 141.3 1 Atkins, J. M. et al., Am. J. Oph. 99:173-175, Feb., 1985. a Twice the clinical concentration. *Mean pulse rate significantly lower for timolol than betaxolol or placebo (p < 0.05).
Clinical Studies Optic nerve head damage and visual field loss are the result of a sustained elevated intraocular pressure and poor ocular perfusion. Betaxolol Hydrochloride Ophthalmic Solution has the action of reducing elevated as well as normal intraocular pressure, and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry.
The onset of action with Betaxolol Hydrochloride Ophthalmic Solution can generally be noted within 30 minutes and the maximal effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in intraocular pressure. Clinical observation of glaucoma patients treated with Betaxolol Hydrochloride Ophthalmic Solution for up to three years shows that the intraocular pressure lowering effect is well maintained.
Clinical studies show that topical Betaxolol Hydrochloride Ophthalmic Solution reduces mean intraocular pressure 25% from baseline. In trials using 22 mmHg as a generally accepted index of intraocular pressure control, Betaxolol Hydrochloride Ophthalmic Solution was effective in more than 94% of the population studied, of which 73% were treated with the beta blocker alone.
In controlled, double-masked studies, the magnitude and duration of the ocular hypotensive effect of Betaxolol Hydrochloride Ophthalmic Solution and ophthalmic timolol solution were clinically equivalent. Betaxolol Hydrochloride Ophthalmic Solution has also been used successfully in glaucoma patients who have undergone a laser trabeculoplasty and have needed additional long-term ocular hypotensive therapy.
Betaxolol Hydrochloride Ophthalmic Solution has been well tolerated in glaucoma patients wearing hard or soft contact lenses and in aphakic patients. Betaxolol Hydrochloride Ophthalmic Solution does not produce miosis or accommodative spasm which are frequently seen with miotic agents. The blurred vision and night blindness often associated with standard miotic therapy are not associated with Betaxolol Hydrochloride Ophthalmic Solution.
Thus, patients with central lenticular opacities avoid the visual impairment caused by a constricted pupil.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Betaxolol (as hydrochloride) |
| PNF listing | Eye Drops Suspension: 0.25%, 5 mL bottle Eye Drops Solution: |
| PNF listing | Eye Drops Suspension: 0.5%, 5 mL and 10 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Betaxolol Hydrochloride · Sandoz Inc [US FDA-approved label, version 10, October 31, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a73519d5-546c-4377-92ed-0d4be2685d60
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .